ERBB2 and breast cancer: In this prospective study, HER2-positive BC participants treated with trastuzumab and/or pertuzumab in combination with nonanthracycline-based chemotherapy underwent cardiac MRI immediately before treatment initiation as well as 3 months after the start of treatment.